Comparison of oncological outcomes of right-sided colon cancer versus left-sided colon cancer after curative resection

Dae Ro Lim, MD, Jung Kul Kuk, MD, Taehyung Kim, MD, Eung Jin Shin, MD, PhD∗

1. Introduction
Colorectal cancer is one of the most common cancers in the world, and it is the fourth most common cancer among both men and women in Asian countries (1998–2007). In Korea, colorectal cancer is the third most common cancer in general, the second most common cancer among men, and the third most common cancer among women. The mainstay treatment of colon cancer is surgical resection. The surgeries performed for colon cancer, according to location of tumor, are right hemicolectomy, extended right hemicolectomy, left hemicolectomy, and anterior resection. There is evidence that right-sided colon cancer (RCC) is different from left-sided colon cancer (LCC) and rectal cancer. There are embryological origins, as well as anatomical, histological, genetic, and immunological differences between RCC and LCC. During embryological development, the right-sided colon (cecum, ascending colon, and proximal two-thirds of the transverse colon) arises from the hindgut, while the left-sided colon (distal one-third of the transverse colon, descending colon, and sigmoid colon) arises from the hindgut. The characteristics of RCC are associated with iron deficiency anemia, advanced stage, and old age. Furthermore, RCC tends to involve bulky, exophytic, polypoid lesions growing into the colon lumen. In contrast, the characteristics of LCC tend to involve infiltrating, constricting lesions encircling the colorectal lumen and causing obstruction. It has been shown that patients with RCC are older and more often female, and the disease is associated with advanced tumor stages, increased tumor size, more frequent poorly differentiated tumors, and different molecular biological tumor patterns. For the reasons described above, many studies have reported that oncologic

Abstract
Propose: There are embryological origins, anatomical, histological, genetic, and immunological differences between right-sided colon cancer (RCC) and left-sided colon cancer (LCC). Many studies have sought to determine the survival and prognosis according to tumor location. This study aimed to analyze outcomes between RCC and LCC.

Material and method: Between January 2000 and December 2012, data on 414 patients who underwent curative resection for RCC and LCC were retrieved from a retrospective database. Propensity score matching (1:1) was performed and RCC was identified in 207 and LCC in 207 patients.

Results: On average, RCC exhibited a more advanced N stage, increased tumor size, more frequently poorly differentiated tumors, more harvested lymph nodes, and more positivity of lymphovascular invasion than LCC. With a median follow-up of 66.7 months, the 5-year overall survival (OS) rates for RCC and LCC were 82.1% and 88.7%, respectively, (P < .05). The 5-year disease-free survival (DFS) rates were 81.4% (RCC) and 88.3% (LCC; P < .05). In stage III cancers, the DFS rates were 61.1% (RCC) and 81.9% (LCC; P < .05), while the OS rates were 65.6% (RCC) and 78.6% (LCC; P = .056).

Conclusion: On the basis of present data, LCC exhibited better survival outcomes than RCC after curative resection. Especially in stage III, LCC showed better oncologic outcomes. Proper specialized treatment related to the location of colon cancer is needed.

Abbreviations: AJCC = American Joint Committee on Cancer, ASA = American society of anesthesiologists, BMI = body mass index, CEA = carcinoembryonic antigen, CT = computed tomography, DFS = disease-free survival, LCC = left-sided colon cancer, MSI = microsatellite instability, OS = overall survival, PET = positron emission tomography, RCC = right-sided colon cancer, TNM = tumor node metastasis.

Keywords: colonic neoplasms, location, outcome
outcomes of colon cancer are different according to the location of tumor. Most studies have reported poorer oncologic outcomes in patients with RCC compared with patients with LCC.\textsuperscript{[6,13]} However, recent studies have reported that the prognosis of localized RCC is better than that of LCC.\textsuperscript{[14,15]} The present study aimed to analyze clinicopathological findings and oncologic outcomes between RCC and LCC after curative resection.

2. Materials and methods

Between January 2000 and December 2012, 563 patients who underwent curative surgery for right-sided and left-sided colon adenocarcinomas were identified from a retrospective database. Patients with stage IV disease were excluded from the present study, as were patients with metastatic and synchronous cancer. All data on clinical and pathological features were reviewed retrospectively. RCC was defined as location of the tumor, including the cecum/appendix, ascending colon, hepatic flexure, and proximal transverse colon (proximal two-thirds of the transverse colon). LCC was defined as location of the tumor, including the distal transverse colon (distal one-third of the transverse colon), splenic flexure, descending colon, and sigmoid colon. Rectosigmoid colon cancer and rectal cancer were excluded in the present study. All patients underwent colonoscopy, biopsy, and staging scans [chest, abdomen, and pelvis computed tomography (CT) scans], and occasionally, positron emission tomography (PET) scans were performed. All patients underwent curative resection. Adjuvant chemotherapy was carried out with 5-fluorouracil and a leucovorin-based regimen [6 cycles of monthly bolus intravenous administration of 5-fluorouracil (400–425 mg/m\textsuperscript{2}/day) and leucovorin (20 mg/m\textsuperscript{2}/day) days 1–5]. The reasons for not performing postoperative adjuvant chemotherapy included advanced age, patient refusal, and the side effects of adjuvant chemotherapy. Patients received close follow-up and were included in a database until July 2016 or their death if this occurred before July 2016. Disease-free survival (DFS) was defined as extending from the date of surgery to the date of the detection of recurrence, the last follow-up, or death. Patients in the 2 groups were compared with respect to patient demographics, peri- and postoperative morbidity, and pathological and oncologic outcomes.

2.1. Statistical analysis

All statistical analyses were performed using SAS Version 9.1.3 (SAS Institute Inc., Cary, NC) and SPSS software, Version 24.0 (SPSS, Chicago, IL). Categorical variables were analyzed using the $\chi^2$ or Fisher exact test, and continuous variables were analyzed using the Student $t$ test/Mann–Whitney U rank test. Cumulative-incidence methods were used to estimate the rate of cancer recurrence. Overall survival (OS) and DFS were analyzed using the Kaplan–Meier method, and a comparison was performed using the log-rank test. In the results, $P$ values less than .05 were considered statistically significant. The differences in OS and DFS were assessed using the log-rank test.

Propensity score matching was performed (1:1 matching method). Propensity score matching was performed for the original 563 patients, a 1:1 matching method stratified into 2 groups, as follows (total 418 patients): Group I included 207 patients with RCC who underwent curative resection, and Group II included 207 patients with LCC who underwent curative resection. Internal validation was performed by the bootstrap method using the new datasets created by random drawing from the sample with replacement. In each of the new data sets ($n = 1000$), the Cox proportional hazard model about the OS and DFS was repeated. Analyses were performed using R version 3.4.3 (R Foundation for Statistical Computing, Vienna, Austria, http://www.R-project.org/).

3. Results

3.1. Patient characteristics

Patient characteristics were analyzed through a comparison of Group I and Group II (Table 1). Mean age, sex ratio, height, weight, BMI, ASA score, initial CEA, and tumor location were analyzed (Table 1). In the results, $P$ values were less than .05 and considered statistically significant.

| Table 1 |
|---|
| Patient characteristics ($n = 414$). | Right side colon ($n = 207$) (%) | Left side colon ($n = 207$) (%) | $P$ |
| Age [mean±SD, (range)], y | 62.9±12.5 (36–85) | 62.1±11.4 (33–84) | .334 |
| Sex, n (%) | | | 1.000 |
| Male | 109 (52.7%) | 109 (52.7%) | |
| Female | 98 (47.3%) | 98 (47.3%) | |
| Weight [mean±SD, (range)], kg | 59.6±9.7 (38.6–91.7) | 60.4±10.3 (38.9–105.8) | .405 |
| Height [mean±SD, (range)], cm | 159.1±9.2 (137.5–185.8) | 160.0±9.2 (131.0–180.4) | .961 |
| BMI [mean±SD, (range)], kg/m\textsuperscript{2} | 23.5±3.3 (16.9–33.7) | 23.5±2.9 (15.3–34.5) | .207 |
| ASA score, n (%) | | | .765 |
| 1 | 76 (36.7%) | 80 (38.6%) | |
| 2 | 125 (60.4%) | 119 (57.5%) | |
| 3 | 6 (2.9%) | 8 (3.9%) | |
| Initial CEA | 5.4±8.1 (0.19–113.41) | 5.9±10.8 (0.30–70.92) | .152 |
| Tumor location | | | NS |
| Right side | | | |
| Cecum | 7 (3.4%) | | |
| Ascending colon | 140 (67.6%) | | |
| Hepatic flexure colon | 7 (3.4%) | | |
| Proximal transverse colon | 53 (25.6%) | | |
| Left side | | | |
| Distal transverse colon | | 7 (3.4%) | |
| Splenic flexure colon | | 2 (1.0%) | |
| Descending colon | | 24 (11.6%) | |
| Sigmoid colon | | 174 (84.0%) | |
weight, body mass index (BMI), and ASA scores, as well as initial CEA, did not significantly differ between the 2 groups. The distribution of RCC was 3.4% cecum (n=140), 3.4% hepatic flexure colon (n=7), and 25.6% proximal transverse colon (n=53). The distribution of LCC was 3.4% distal transverse colon (n=7), 1.0% splenic flexure colon (n=2), 11.6% descending colon (n=24), and 84.0% sigmoid colon (n=174).

### 3.2. Pathological results

The tumor–node–metastasis (TNM) stage, pT stage, pN stage, and pM stage were classified according to the American Joint Committee on Cancer (AJCC, 7th edition). In the distribution of TNM stage, the N stage was significantly different between the 2 groups except the T stage. The histological grades of differentiation significantly differed between the 2 groups (P=0.019). Group II had more patients with a moderate differentiation of cancer (n=152, 73.4% in Group II vs n=118, 57.0% in Group I; P<.005). The mean numbers of harvested lymph nodes were 30.3±17.2 in Group I and 16.3±11.1 in Group II (P<.005). The mean proximal resection margins in Groups I and II were 14.7±9.4 and 9.2±4.9 cm, respectively (P<.005). The mean distal resection margins were 15.9±9.5 and 6.1±4.9 cm, respectively (P<.005). The mean specimen mass sizes were 5.6±3.1 cm in Group I and 4.4±2.3 cm in Group II (P=.008). The lymphovascular invasion rates were 38.6% in Group I and 28.1% in Group II (P=.022). The perineural invasion rates were 15.0% in Group I and 10.1% in Group II (P=.138; Table 2).

### 3.3. Oncologic outcomes

With a median follow-up of 66.7 months, the 5-year DFS rates were 81.4% in Group I and 88.3% in Group II (P=.031). The 5-year OS rates were 82.1% in Group I and 88.7% in Group II (P=.012; Fig. 1). For stage I, the 5-year DFS rates were 97.7% in Group I and 100.0% in Group II (P=.66). For stage II, the 5-year DFS rates were 89.3% in Group I and 84.6% in Group II (P=.564). The 5-year OS rates were 87.4% in Group I and 87.9% in Group II (P=.633; Fig. 2). For stage III, the 5-year DFS rates were 61.1% in Group I and 81.9% in Group II (P=.008). The 5-year OS rates were 65.6% in Group I and 78.6% in Group II (P=.056; Fig. 3).

### 3.4. Univariate and multivariate analysis of prognostic factors

Old age (≥70 years), tumor location (right side), large tumor size (≥5 cm), T3-4 stage, node-positive stage (N1-2), histological

---

*Table 2: Postoperative pathologic outcomes.*

|          | Right side colon (n=207) (%) | Left side colon (n=174) (%) | P   |
|----------|-----------------------------|-----------------------------|-----|
| pT stage, no. (%) |                             |                             |     |
| 0        | 4 (1.9%)                    | 5 (2.4%)                    | 1.38|
| 1        | 39 (18.6%)                  | 53 (25.6%)                  |     |
| 2        | 88 (42.5%)                  | 80 (38.6%)                  |     |
| 3        | 3 (1.4%)                    | 4 (1.9%)                    |     |
| 4a       | 2 (1.0%)                    | 2 (1.0%)                    |     |
| 4b       | 7 (3.4%)                    | 11 (5.3%)                   |     |
| 4c       | 41 (19.8%)                  | 44 (21.3%)                  |     |
| 4d       | 23 (11.1%)                  | 8 (4.9%)                    |     |
| pH stage, no. (%) |                             |                             | 0.19|
| 0        | 136 (65.7%)                 | 144 (69.6%)                 |     |
| 1        | 27 (13.0%)                  | 41 (19.6%)                  |     |
| 2        | 20 (9.7%)                   | 23 (9.9%)                   |     |
| 3        | 140 (67.6%)                 | 128 (61.1%)                 |     |
| 4a       | 13 (6.3%)                   | 7 (3.4%)                    |     |
| 4b       | 3 (1.4%)                    | 3 (1.4%)                    |     |
| Grade of differentiation, no. (%) |                             |                             | <.005|
| Well     | 40 (19.3%)                  | 44 (21.3%)                  |     |
| Moderate | 118 (57.0%)                 | 152 (73.4%)                 |     |
| Poor     | 28 (13.5%)                  | 9 (4.3%)                    |     |
| Mucinous | 19 (9.2%)                   | 2 (1.0%)                    |     |
| Signet ring cell |                             |                             |     |
| Harvested no. of lymph nodes, (mean±SD, range) | 30.3±17.2 (1–94) | 16.3±11.1 (1–72) | <.005|
| Lymphovascular invasion |                     |                             | 0.022|
| –        | 127 (61.4%)                 | 149 (71.9%)                 |     |
| +        | 80 (38.6%)                  | 58 (28.1%)                  |     |
| Perineural invasion |                             |                             | 0.138|
| –        | 176 (85.0%)                 | 186 (99.9%)                 |     |
| +        | 31 (15.0%)                  | 21 (10.1%)                  |     |
| pTNM, (mean±SD, range), cm | 14.7±9.4 (2.8–58.0) | 9.2±4.9 (1.5–28.0) | <.005|
| DRM, (mean±SD, range), cm | 15.9±9.5 (6.5–59.0) | 6.1±4.9 (1.0–54.0) | <.005|
| Mass size | 5.6±3.1 (0.5–15.0) | 4.4±2.3 (0.7–10.0) | 0.008|

---

*Figure 1.* Five-year disease-free survival rate (A) and 5-year overall survival rate (B) of right-sided colon cancer and left-sided colon cancer after curative surgery.
grade, and lymphovascular invasion were analyzed as poor prognostic factors for the OS rate after surgery in univariate analysis (Table 3.). The old age (≥70 years), T3-4 stage, and node-positive stage (N1-2) were analyzed as a poor prognostic factor for the OS rate after surgery in multivariate analysis. In addition, tumor location (right side), large tumor size (≥5 cm), T3-4 stage, node-positive stage (N1-2), histological grade, lymphovascular invasion, and perineural invasion were analyzed as prognostic factors for the DFS rate after surgery in univariate analysis. The T3-4, node-positive stage (N1-2), and histological

**Table 3**

Univariate and multivariate analysis for prognostic factor of overall survival after surgery for colon cancer.

| Factors                                      | Univariate analysis | Multivariate analysis |
|----------------------------------------------|---------------------|-----------------------|
|                                              | HR                  | 95% CI                | P        | HR                  | 95% CI                | P        |
| Age, y (<70 vs ≥70)                          | 2.19                | 1.31–3.55             | .003     | 2.07                | 1.25–3.41             | .005     |
| Sex (Male vs Female)                         | 0.94                | 0.82–0.94             | .821     |                     |                      |          |
| BMI (<25 vs ≥25)                             | 0.64                | 0.36–1.14             | .118     |                     |                      |          |
| Tumor location (Rt. side vs Lt. side)        | 0.52                | 0.31–0.87             | .011     | 0.71                | 0.41–1.24             | .229     |
| Tumor size, cm (<5 vs ≥5)                    | 2.76                | 1.61–4.72             | <.05     | 1.48                | 0.83–2.67             | .186     |
| T stage (T1-2 vs T3-4)                       | 8.48                | 2.67–27.07            | <.05     | 4.12                | 1.20–14.08            | .024     |
| N stage (N0 vs N1-2)                         | 2.94                | 1.79–4.84             | <.05     | 2.09                | 1.23–3.54             | .006     |
| Number of harvested lymph node (<12 vs ≥12)  | 1.24                | 0.68–2.24             | .477     |                     |                      |          |
| Histological grade (Well-mod. vs others)     | 3.02                | 1.76–5.18             | <.05     | 1.64                | 0.91–2.94             | .097     |
| Lymphovascular invasion (present vs absent)  | 2.56                | 1.56–4.21             | <.05     | 1.37                | 0.80–2.35             | .249     |
| Perineural invasion (present vs absent)      | 1.78                | 0.95–3.33             | .002     |                     |                      |          |

CI = confidence interval, HR = hazard ratio.
grade were analyzed as prognostic factors for the DFS rate after surgery in multivariate analysis (Table 4).

3.5. Internal validation

Stability in the result of Cox PH analyses for OS and DFS was assessed over the 1000 bootstrap samples. In the case of OS, age, T stage, and N stage were selected in all 1000 bootstrap samples and BMI, tumor size, histologic grade, and lymphovascular invasion were selected in 13.4%, 11.5%, 17.9%, and 24.3% of the cases, respectively, and there was left out of the model, including the tumor location that was the primary factor in this study. In the case of DFS, T stage, N stage, and histologic grade were selected in all 1000 bootstrap samples and tumor size, lymphovascular invasion, and perineural invasion were selected in 28.9%, 10.8, and 37.7% of the cases, respectively, and therefore left out of the model including the tumor location as the above reason.

4. Discussion

Colon cancer has different clinicopathological features and genetic differences between the right side and the left side. Many studies have reported that patients with RCC are older and more often female; moreover, they have more advanced tumor stages, increased tumor size, more often poorly differentiated tumors, and different molecular biological tumor patterns. In addition, MSI-high cancer has been reported to be more frequent than in RCC.

Several studies have reported that LCC is more represented in patients older than 60 years of age compared with RCC. In the present study, the distribution of age was relatively equal (P = 1.000). A nationwide Danish cohort study was reported that a significantly higher proportion of RCC (56.8%) than LCC (46%) patients were women (P < .0001).

Several studies have reported that LCC more often represents an early-stage disease compared with RCC, and these results have affected the disparity in prognoses according to the location of tumors. Similarly, several studies have reported that RCC tends to exhibit a more advanced stage compared with LCC. In the present study, although there were not significant differences between the 2 groups, especially, stage IIc was more often found in RCC (11.1%) than in LCC (3.9%; P = .138). The distribution of the T stage was not significantly different between the 2 groups (P = .354). However, distribution of the N stage was significantly different between the 2 groups (P = .019), especially N2b (right side; 10.6% vs left side; 2.4%). In addition, RCC is more poorly differentiated (13.5% vs 4.3%), mucinous (9.2% vs 1.0%), and likely to exhibit signet ring cells (1.0% vs 0%) compared with LCC in histological grade (P < .005). Previous studies reported that higher proportions of poorly differentiated cancers were noted in RCCs more frequently than in LCCs.

Mik et al reported that the total number of harvested lymph nodes was higher in the RCC group than in the LCC group (11.7 ± 6 vs 8.3 ± 5; P = .0001). The lymph node ratio was higher in the LCC group (0.45 ± 0.28 vs 0.30 ± 0.25; P = .0063). A recent

### Table 4

| Factors                              | Univariate analysis | Multivariate analysis |
|--------------------------------------|---------------------|-----------------------|
|                                      | HR      | 95% CI     | P   | HR      | 95% CI     | P   |
| Age, y (<70 vs ≥70)                  | 1.36    | 0.80–2.31  | .258| 0.84    | 0.48–1.48  | .545|
| Sex (Male vs female)                 | 1.31    | 0.79–2.19  | .206| 1.72    | 0.92–1.54  | .088|
| BMI (<25 vs ≥25)                     | 0.84    | 0.48–1.48  | .545| 0.69    | 0.30–1.54  | .321|
| Tumor location (Rt. vs Lt. side)     | 0.56    | 0.33–0.96  | .031| 0.84    | 0.48–1.47  | .544|
| Tumor size, cm (<5 vs ≥5)            | 3.28    | 2.04–5.3  | .05 | 1.72    | 0.92–3.24  | .088|
| N stage (T1-2 vs T3-4)               | 12.8    | 3.12–53.4  | .05 | 2.31    | 1.32–4.05  | .003|
| Number of harvested lymphnode (<12 vs ≥12) | 3.67    | 2.18–6.2  | .05 | 2.31    | 1.32–4.05  | .003|
| Histological grade (Well- vs others)  | 3.59    | 2.09–6.6  | .05 | 1.77    | 0.98–3.22  | .045|
| Lymphovascular invasion (present vs absent) | 2.71    | 1.73–4.25 | .05 | 1.33    | 0.76–2.36  | .320|
| Perineural invasion (present vs absent) | 2.32    | 1.27–4.22 | .011| 1.29    | 0.69–2.40  | .428|

**HR** = hazard ratio, **CI** = confidence interval.
study reported that RCC patients exhibited more lymph nodes (18.7 vs 16.3) compared with LCC patients, and RCC patients were more likely to have ≥12 nodes (P < .001), whereas RCC showed lower rates of node positivity (P < .001). The reasons for these node-status differences were field of surgery and differences in the immune response and molecular features between RCC and LCC. The field of resection in right hemicolectomy is wider compared with that of left hemicolectomy or anterior resection. Anatomically, the right-sided colon mesentery may contain a more complex lymphatic system, leading to an enhanced immune response and an increased number of lymph nodes examined for RCC. In the present study, the total number of harvested lymph nodes was higher in Group I than in Group II (30.3 ± 17.2 vs 16.3 ± 11.1; P < .005). Moreover, the rate of node positivity in Group I was higher than that in Group II (34.3% vs 30.4%; P = .019). For these reasons, in accordance with previous studies, RCC was associated with poorer oncologic outcomes compared with LCC in this research. Indeed, previous studies have reported poorer oncologic outcomes in patients with RCC compared with patients with LCC. The 5-year OS rate was 82.1% in Group I and 88.7% in Group II (P = .012). In more detail, at stage I and II, there were no significant differences between the 2 groups, although the oncologic outcomes for RCC were low compared with those associated with LCC. In stage III, there were significant differences between the 2 groups (DFS: 61.1% vs 81.9%, P = .008; OS, 65.6% vs 78.6%, P = .056).

In present study, the T3-4 stage and node-positive stage (N1-2) were analyzed as prognostic factors for the OS and DFS rate after surgery in multivariate analysis. Of course, tumor location (right side/left side) is not an independent prognostic factor for the OS and DFS rate after surgical treatment in colon cancer. In present study, it was also not analyzed as an independent prognostic factor in multivariate analysis. However, as shown in multivariate analysis in present study, advanced T stage, node positivity, and poor histological grade were an independent prognostic factor for oncologic outcomes. The RCC trend to have more advanced T stage, node positivity, and poor histological grade than the LCC. Therefore, the prognosis of RCC is expected to be worse compared with LCC, relatively. In the present study, it was also analyzed that the RCC trend to have more advanced node positivity (N2a-b; 15.4% vs 8.2, P = .019) and poor histological grade (poorly/mucinous; 21.7% vs 5.3%, P < .005) than the LCC. The present study has several limitations, including its retrospective study, significant selection biases, small sample size, and single center study. Nevertheless, the present study has shown results similar to those of previous studies. The present study has tried to minimize such bias. All patients in the present study are Koreans and all surgeries were performed in 1 hospital. Propensity score matching and internal validation was performed. The present study was a comparison between the 2 groups in these patients, and several factors affecting results were no significant difference between the 2 groups.

In conclusion, RCC was associated with more advanced stage, increased tumor size, more often poorly differentiated tumors, more harvested lymph nodes, and more node positivity than LCC in the present study. On the basis of present data, LCC has better survival outcome compared with RCC after curative resection (especially for stage III). More large-scaled studies are needed and proper specialized treatment related to the location of colon cancer is needed.

References

[1] Brenner H, Kloor M, Pox CP. Colorectal cancer. Lancet 2014;383:1490–502.
[2] Park HM, Woo H, Jung SJ, et al. Colorectal cancer incidence in 5 Asian countries by subsite: an analysis of colorectal cancer incidence in five continents (1998–2007). Cancer Epidemiol Biomarkers Prev 2016;25:65–70.
[3] Korea Central Cancer Registry National Cancer Center. Annual Report of Cancer Statistics in Korea in 2011. Ministry of Health and Welfare; 2013.
[4] Hansen JO, Jess P. Possible better long-term survival in left versus right-sided colon cancer: a systematic review. Dan Med J 2012;59:4444.
[5] Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 1990;113:779–91.
[6] Bale AL, Penney MD, Allison MC. The prevalence of iron deficiency among patients presenting with colorectal cancer. Colorectal Dis 2005;7:398–402.
[7] Saltzstein SL, Behling CA. Age and time as factors in the left to right shift of the subute of colorectal adenocarcinoma: a study of 213,383 cases from the California Cancer Registry. J Clin Gastroenterol 2007;41:173–7.
[8] Powell AG, Wallace R, McKee RF, et al. The relationship between tumour site, clinicopathological characteristics and cancer-specific survival in patients undergoing surgery for colorectal cancer. Colorectal Dis 2012;14:1493–9.
[9] Benedix P, Kube R, Meyer F, et al. Colon/Rectum Carcinomas (Primary Tumor) Study Group/Comparison of 17,641 patients with right and left sided colon cancer: differences in epidermal, peripheric growth course, histology, and survival. Dis Colon Rectum 2010;53:57–64.
[10] Sutte SA, Shukll I, Mullen R, et al. Outcome of right- and left-sided colon and rectal cancer following surgical resection. Colorectal Dis 2011;13:884–9.
[11] Huang CW, Tsoi HL, Huang MY, et al. Different clinicopathologic features and favorable outcomes of patients with stage III left-sided colon cancer. World J Surg Oncol 2015;13:257.
[12] Mioguid RA, Sidell MB, Wolfgang GL, et al. Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol 2008;15:2388–94.
[13] Jess P, Hansen RO, Gamborg M, et al. Danish Colorectal Cancer Group. A nationwide Danish cohort study showing the categorization into right-sided and left-sided colon cancer. BMJ Open 2013;3:e002608.
[14] Warschlow R, Sulz MC, Martl L, et al. Better survival in right-sided versus left-sided stage I-III colon cancer patients. BMC Cancer 2016;16:534.
[15] Moritani K, Hasegawa H, Okabayashi K, et al. Difference in the recurrence rate between right- and left-sided colon cancer: a 17-year experience at a single institution. Surg Today 2014;44:1685–91.
[16] Markowitz SB, Bertagnoli MM. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009;361:2449–60.
[17] Shin US, Cho SS, Moon SM, et al. Is microsatellite instability really a good prognostic factor of colorectal cancer? Ann Coloproctol 2014;30:28–34.
[18] Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin 2014;64:104–17.
[19] Christodoulidis G, Sypridakis M, Symeonidis D, et al. Clinicopathological differences between right- and left-sided colonic tumors and impact upon survival. Tech Coloproctol 2010;14:45–7.
[20] Roncucci L, Fante R, Losi L, et al. Survival for colon and rectal cancer in a population based cancer registry. Eur J Cancer 1996;32:295–302.
[21] Sariego J, Byrd ME, Kerstein M, et al. Changing patterns in colorectal carcinoma: a 25-year experience. Am Surg 1992;58:868–91.
[22] Hussain M, Waqas O, Hassan U, et al. Right-sided and Left-sided colorectal cancers are two distinct disease entities: an analysis of 200 cases in Pakistan. Asian Pac J Cancer Prev 2016;17:2345–8.
[23] Ishihara S, Watanabe T, Akahane T, et al. Tumor location is a prognostic factor in poorly differentiated adenocarcinoma, mucinous adenocarcinoma, and signet-ring cell carcinoma of the colon. Int J Colorectal Dis 2012;27:371–9.
[24] Mik M, Berut M, Dziki L, et al. Right- and left-sided colon cancer: clinical and pathological differences of the disease entity in one organ. Arch Med Sci 2017;13:157–62.
[25] Guan X, Chen W, Liu Z, et al. Whether regional lymph nodes evaluation should be equally required for both right and left colon cancer. Onco-target 2016;13:59945–56.
[26] Bilimoria KY, Palis B, Stewart AK, et al. Impact of tumor location on nodal evaluation for colon cancer. Dis Colon Rectum 2008;51:1334–61.
[27] Shen H, Yang J, Huang Q, et al. Different treatment strategies and molecular features between right sided and left sided colon cancers. World J Gastroenterol 2015;21:6470–8.
[28] Yahagi M, Okabayashi K, Hasegawa H, et al. The worse prognosis of right-sided compared with left-sided colon cancers: a systematic review and meta-analysis. J Gastrointest Surg 2016;20:648–55.
[29] Lee GH, Malietzis G, Askari A, et al. Is right-sided colon cancer different to left-sided colorectal cancer? A systematic review. Eur J Surg Oncol 2015;41:300–8.
[30] Petrelli F, Tomasello G, Borgonovo K, et al. Prognostic survival associated with left-sided vs right-sided colon cancer: a systematic review and meta-analysis. JAMA Oncol 2016;27:4227.